肺力咳合剂联合哌拉西林钠他唑巴坦钠治疗慢性支气管炎急性发作的效果及对机体炎症因子表达的影响

Effect of pulmonary cough combination combined with piperacillin sodium tazobactam sodium in the treatment of acute exacerbation of chronic bronchitis and its effect on the expression of inflammatory factors in the body

目的分析肺力咳合剂联合哌拉西林钠他唑巴坦钠治疗慢性支气管炎急性发作的效果及对机体炎症因子表达的影响。方法选取2019年1月至2021年1月本院收治的60例慢性支气管炎急性发作患者作为研究对象,按照单双号分为对照组和实验组,每组30例。对照组采用静脉滴注哌拉西林钠他唑巴坦钠治疗,实验组采用肺力咳合剂联合哌拉西林钠他唑巴坦钠治疗,比较两组临床疗效、肺功能指标[第1秒钟用力呼气容积占用力肺活量的比值(FEV_(1)/FVC)、每分钟最大通气量(MVV)、最大呼气中期流量(MMEF)]改善情况、炎症因子指标[白细胞(WBC)、降钙素原(PCT)、转化生长因子-β(TGF-β)]、临床症状恢复时间和治疗前后血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、氢离子浓度指数(pH)]。结果实验组治疗总有效率为93.33%,高于对照组的66.67%,差异有统计学意义(P<0.05)。实验组FEV_(1)/FVC、MVV、MMEF均高于对照组,差异有统计学意义(P<0.05)。治疗前,两组WBC、PCT、TGF-β水平比较差异无统计学意义;治疗后,两组WBC、PCT、TGF-β水平均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。实验组咳嗽恢复时间、体温恢复时间及肺部啰音消失时间均短于对照组,差异有统计学意义(P<0.05)。治疗前,两组PaO2、PaCO_(2)水平及pH值比较差异均无统计学意义;治疗后,两组PaO2水平均高于治疗前,pH值均大于治疗前,PaCO_(2)水平均低于治疗前,且实验组PaO2水平高于对照组,pH值大于对照组,PaCO_(2)水平低于对照组,差异有统计学意义(P<0.05)。结论采用肺力咳合剂联合哌拉西林钠他唑巴坦钠治疗慢性支气管炎急性发作患者可有效提高临床疗效,降低炎症因子水平,加快患者康复,值得临床推广应用。

Objective To analyze the effect of pulmonary cough combination combined with piperacillin sodium tazobactam sodium in the treatment of acute exacerbation of chronic bronchitis and its effect on the expression of inflammatory factors.Methods A total of 60 patients with acute onset of chronic bronchitis admitted to our hospital from January 2019 to January 2021 were selected as the research subjects,and they were divided into control group and experimental group according to single and even numbering method,with 30 cases in each group.the control group was treated with intravenous drip piperacillin sodium tazobactam sodium,and the experimental group was treated with pulmonary cough mixture combined with piperacillin sodium tazobactam sodium,and the clinical treatment effect and lung function improvement(the ratio of forced expiratory volume in one second to forced vital capacity[FEV_(1)/FVC],maximum ventilation per minute[MVV],maximum mid-expiratory flow[MMEF]),inflammatory factor indexes(leukocytes[WBC],procalcitonin[PCT],transforming growth factor-β[TGF-β])levels,time to recovery of clinical symptoms,and blood gas analysis results before and after treatment(arterial partial pressure of oxygen[PaO_(2)],partial pressure of arterial carbon dioxide[PaCO_(2)],hydrogen ion concentration index[pH])were compared between the two groups.Results The total effective rate of treatment in the experimental group was 93.33%,which was higher than 66.67%in the control group,and the difference was statistically significant(P<0.05).The FEV_(1)/FVC,MVV and MMEF in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels ofWBC,PCT,and TGF-βbetween the two groups;after treatment,the levels ofWBC,PCT,TGF-βin the two groups were lower than those before treatment,and the experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).The cough recovery time,body temperature recovery time,and pulmonary rale disappearance time in the experimental group were all shorter than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of PaO_(2),PaCO_(2)and pH value between the two groups;after treatment,the PaO_(2)level of two groups was higher than that before treatment,the pH value was greater than that before treatment,the PaCO_(2)level was lower than that before treatment,and the PaO_(2)level of the experimental group was higher than that of the control group,the PH value was greater than that of the control group,and the PaCO_(2)level was lower than that of the control group,and the differences were statistically significant(P<0.05).Conclusion The use of pulmonary cough mixture combined with piperacillin sodium tazobactam sodium in the treatment of patients with acute exacerbation of chronic bronchitis can effectively improve clinical efficacy,reduce the level of inflammatory factors,and accelerate the recovery of patients,which is worthy of clinical promotion and application.